SK Biopharmaceuticals remains in red in 2023
SEOUL, SK Biopharmaceuticals Co. on Monday reported its 2023 net loss of 36.3 billion won (US$27.2 million), remaining in the red compared with the previous year.
The company said in a regulatory filing that it continued to post an